88
Participants
Start Date
September 30, 2014
Primary Completion Date
September 12, 2018
Study Completion Date
October 17, 2018
Abatacept
Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks
Placebo
125 mg of Placebo
Hospital for Special Surgery, New York
Columbia University, New York
NorthWell Health, Great Neck
Steffens Scleroderma Center, Albany
University of Pittsburgh, Pittsburgh
University of Pennsylvania, Philadelphia
Georgetown University, Washington D.C.
Medical University of South Carolina, Charleston
Ohio State University Medical Center, Columbus
Cleveland Clinic, Cleveland
University of Michigan, Ann Arbor
University of Minnesota, Minneapolis
Mayo Clinic, Rochester
Northwestern University, Chicago
University of Texas Health Center at Houston, Houston
University of Utah, Salt Lake City
Arthritis Associates of Southern California, Los Angeles
University of California- Los Angeles, Los Angeles
Stanford University, Redwood City
Swedish Health Services, Seattle
Harvard Mass General, Boston
Boston University, Boston
Rutgers University Clinical Research Center, New Brunswick
St. Joseph Health Care London, London
Mount Sinai Hospital, Toronto
Jewish General Hospital, Montreal
Royal Free Hospital, London
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Dinesh Khanna, MD, MS
OTHER